Absorbed Dose Estimation of ⁶⁸Ga-EDTMP in Human Organs

S. Zolghadri, H. Yousefnia, A. R. Jalilian

Abstract-Bone metastases are observed in a wide range of cancers leading to intolerable pain. While early detection can help the physicians in the decision of the type of treatment, various radiopharmaceuticals using phosphonates like ⁶⁸Ga-EDTMP have been developed. In this work, due to the importance of absorbed dose, human absorbed dose of this new agent was calculated for the first time based on biodistribution data in Wild-type rats. ⁶⁸Ga was obtained from ⁶⁸Ge/⁶⁸Ga generator with radionuclidic purity and radiochemical purity of higher than 99%. The radiolabeled complex was prepared in the optimized conditions. Radiochemical purity of the radiolabeled complex was checked by instant thin layer chromatography (ITLC) method using Whatman No. 2 paper and saline. The results indicated the radiochemical purity of higher than 99%. The radiolabelled complex was injected into the Wild-type rats and its biodistribution was studied up to 120 min. As expected, major accumulation was observed in the bone. Absorbed dose of each human organ was calculated based on biodistribution in the rats using RADAR method. Bone surface and bone marrow with 0.112 and 0.053 mSv/MBq, respectively, received the highest absorbed dose. According to these results, the radiolabeled complex is a suitable and safe option for PET bone imaging.

Keywords—Absorbed dose, EDTMP, ⁶⁸Ga, rats.

I. INTRODUCTION

BONE metastasis results from primary tumor invasion to bone. Skeletal metastasis is a common cause of severe morbidity [1] which accounts for 70% of all malignant bone tumours [2]. While the vast majority of skeletal cancers are originated from the other cancers rather than primary bone tumors [3], lung cancer, breast cancer, renal cell carcinoma and prostate cancer include approximately 80% of all skeletal metastases [2].

Skeletal metastases can result in severe pain. hypercalcemia, pathologic fracture and spinal cord compression [4], [5]. The quality of life in patients suffering from this abnormality reduced substantially. Despite of the early occurrence of skeletal metastases in the tumour disease, their symptoms are recognized rather late [6]. Bone scans are the most sensitive routine imaging modality [2]. ^{99m}Tc labelled methylene diphosphonate (^{99m}Tc-MDP) is the most frequently used radiotracer [7]. However, with respect to the great importance of early detection in the treatment of the diseases,

S. Zolghadri is with the Material and Nuclear Fuel Research School, Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran (email: szolghadri@aeoi.org.ir).

H. Yousefnia is with the Material and Nuclear Fuel Research School, Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran (e-mail: hyousefnia@ aeoi.org.ir).

A. R. Jalilian. is with the Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran (e-mail: jalilian1971@gmail.com).

studies on the development of novel diagnostic methods using new radiopharmaceuticals are still investigated.

While PET offers superior sensitivity, resolution and quantitative ability in comparison with SPECT [8], some positron emitter radiotracers mostly ¹⁸F-FDG have been developed and utilized for bone PET-imaging [9], [10]. However, higher sensitivity for the detection of osseous metastases was reported in comparison to the other imaging modalities [11], preparation of ¹⁸F needs an on-site cyclotron which restricts its application.

A generator based ⁶⁸Ga radioisotope with its favorable characteristics (t $_{\frac{1}{2}}$ = 68 min, E_p [max]= 1.92 MeV) can be considered as an alternative [12]. Nowadays, ⁶⁸Ga has been radiolabeled with numerous molecules and applied for the detection of various abnormalities [13], [14] indicating promising results.

Bisphosphonates have an established role in the treatment of bone metastases [15] and are the current standard therapy for reducing the frequency of skeletal-related complications radionuclides [16]. Recently, in combination with like phosphonate-containing chelators, ethylenediamine acid) tetra(methylene phosphonic (EDTMP), 1.1hydroxyethylidene diphosphonate (HEDP) and 4-{[(bis(phosphonomethyl)) carbamoyl]methyl}-7,10 bis(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl)acetic acid (BPAMD) have been introduced to reach regions of increased bone turnover and show good results in palliative therapy of painful bone metastases as well as in diagnosis of

bone metastases [17]-[19]. Since ¹⁵³Sm-EDTMP is the only FDA approved boneseeking therapeutic radiopharmaceutical and ¹⁷⁷Lu-EDTMP has demonstrated high bone uptake and fast urinary clearance [20], optimized production of ⁶⁸Ga-EDTMP was reported in the recent years showing significant bone accumulation in healthy rats [21]. However, the absorbed dose of this new agent has not been reported until now.

In this study, ⁶⁸Ga-EDTMP was prepared and its biodistribution in wild-type rats was studied. With respect to the importance of the absorbed dose of non-target organs in developing of new radiopharmaceuticals, the human absorbed dose after injection of ⁶⁸Ga-EDTMP was determined for the first time based on the biodistribution data in the rats using RADAR and the method of Sparks et al. [22].

II. MATERIALS AND METHODS

A. Production and Quality Control of ⁶⁸GaCl₃

⁶⁸Ge/⁶⁸Ga generator was eluted with 0.6 M HCL. In order to achieve ⁶⁸GaCl₃ solution with high specific activity, the first

fraction of the generator eluted by 0.5 mL of HCl was disregarded, and the four next fractions (2.0 mL) were considered for radiolabeling purposes.

The radionuclidic purity of the eluted ⁶⁸Ga from the generator was investigated by the gamma spectrometry of the decayed ⁶⁸Ga samples. While the content of chemical impurities was determined by inductively coupled plasma (ICP-OES) method, the ITLC method was used for studying the radiochemical purity. The radiochemical purity was checked by two solvent systems of 10% ammonium acetate:methanol (1:1 V/V) and 10 mM DTPA solutions.

B. Preparation and Quality Control of ⁶⁸Ga-EDTMP

EDTMP was synthesized from phosphorous acid, ethylenediamine and formaldehyde in the presence of HCl by a modified Mannich-type reaction [14] using phosphorous acid, conc. HCl, ethylenediamine and aq. formaldehyde and recrystallization from water/methanol. Characterization of asprepared sample was done by IR and ¹HNMR methods. The results showed the bands of 3308, 2633, 2311, 1668, 1436, 1356 cm⁻¹ at IR diagram. Also, ¹HNMR (D₂O, d ppm) demonstrates 3.53 (d, J = 12.3 Hz, 8H, -N-CH₂-P=O), 3.85 (s, 4H, -N-CH₂-). 13C NMR (D₂O, d ppm):51.63, 52.73. 31P NMR (D2O, d ppm): 10.52.

⁶⁸Ga-EDTMP was prepared according to the previously reported procedure [21]. Briefly, 5 mg of EDTMP was added to a borosilicate vial containing a certain volume of ⁶⁸GaCl₃, 352 mg of solid HEPES and 200 μ l of 0.1 M acetate buffer. The vial was then heated at hot water bath with the temperature of 50-60 °C for 5 min. The radiochemical purity of the complex was then checked by ITLC method, while saline is used as a mobile phase and Whatman No.2 paper as a stationary phase.

C. Biodistribution Assessment of ⁶⁸Ga-EDTMP in Wild-Type Rats

100 μ L of final ⁶⁸GaCl₃ solution was injected into the wildtype rats through their tail veins. The rats were sacrificed at specified intervals (five rats for each interval), whereas the activity and weigh of their main organs were measured by an HpGe detector and a calibrated balance, respectively. %ID/g for each organ was calculated by dividing the activity of each organ at the selected time to the total injected activity and weigh of the organs.

D. Determination of the Cumulated Activity

The non-decay corrected time activity curves for each organ was plotted, and the accumulated source activity was calculated computing the area under the curves while fitted to a mono-exponential, bi- exponential or uptake and clearance curve. In addition, the curves were extrapolated to infinity by fitting the tail of each curve to a mono-exponential curve. Then, the area under the curve was calculated.

The accumulated activity for animal organs was then extrapolated to the accumulated activity for human organs by the proposed method of Sparks et al. [22] (1):

$$\hat{A} \text{ human organ } = \hat{A} \text{ animal organ}$$

$$\frac{Organ \max (human)}{Body \max (human)}$$

$$\frac{Organ \max (animal)}{Body \max (animal)}$$

$$(1)$$

E. Calculation of Equivalent and Effective Absorbed Dose

Absorbed dose of human organs was calculated by RADAR method and according to the previously reported procedure (2) [23]:

$$D = \tilde{A} \times DF \tag{2}$$

where \tilde{A} is the accumulated activity for each human organ, and DF is the parameter which represents the physical decay characteristics of the radionuclide, the range of the emitted radiations, and the organ size and configuration. In this research, DFs have been taken from the amount presented in OLINDA/EXM software.

III. RESULTS AND DISCUSSIONS

A. Production and Quality Control of ⁶⁸GaCl₃

The HPGe spectrum did not show any radionuclidic impurity. The peaks of 511 and 1077 keV were only observed that originates from 68 Ga (Fig. 1). ITLC chromatogram of 68 GaCl₃ approved the radiochemical purity of higher than 99% (Fig. 2).



Fig. 1 HPGe spectrum of ⁶⁸GaCl₃

International Journal of Medical, Medicine and Health Sciences ISSN: 2517-9969 Vol:13, No:11, 2019



Fig. 2 ITLC chromatogram of ⁶⁸GaCl₃ in 10% ammonium acetate:methanol (1:1 V/V) on silicagel sheets (a) and in 10 mM DTPA solution (pH ~4) on Whatman No. 2 paper (b)

B. Preparation and Quality Control of ⁶⁸Ga-EDTMP

ITLC analysis of the final complex showed the radiochemical purity of higher than 99% (Fig. 3). Using Whatman No. 2 paper and saline, the radiolabelled complex was observed at R_f of 0.9.



Fig. 3 ITLC chromatogram of ⁶⁸GaCl₃ (a) and ⁶⁸Ga-EDTMP (b) in saline using Whatman No. 2 as a stationary phase

C. Biodistribution Assessment of ⁶⁸Ga-EDTMP in Wild-Type Rats

The non-decay corrected %ID/g for each animal organ up to 120 m was calculated as described previously (Fig. 4). As expected, the highest amount of activity was observed in bone, while the activity in the other organs was insignificant. Approximately no activity was perceived in blood after 15 min, which shows vary fast clearance of activity from blood circulation. According to the results, kidney can be considered as a major excretion route.

D. Calculation of Equivalent and Effective Absorbed Dose

The absorbed dose of human organs was computed based on the biodistribution data in Wild-type rats (Table I). The results demonstrated an estimated absorbed dose of 0.006 mSv/MBq to the whole body. The highest equivalent absorbed dose was observed in bone surface and bone marrow with

0.112 and 0.053 mSv/MBq, respectively.



Fig. 4 The non-decay corrected of the percentage of injected dose per gram (%ID/g) in intestine, kidney, bone (a), liver, Spleen and stomach (b) at 4, 24, 72 and 168 h after intravenously injection of ⁶⁸Ga-EDTMP into Wild-type rats

TABLE I EQUIVALENT ABSORBED DOSE DELIVERED INTO HUMAN ORGANS AFTER

| Target Organs | Equivalent absorbed dose in humans (mSv/MBq) |
|-------------------|---|
| GB Wall | 0.001 |
| LLI Wall | 0.003 |
| Small Int | 0.001 |
| Stomach Wall | 0.001 |
| ULI Wall | 0.001 |
| Heart Wall | 0.001 |
| Kidneys | 0.003 |
| Liver | 0.001 |
| Lungs | 0.001 |
| Muscle | 0.001 |
| Red Marrow | 0.053 |
| Bone Surf | 0.112 |
| Spleen | 0.001 |
| UB Wall | 0.001 |
| Total Body | 0.006 |

GW: Gallbladder Wall; LLI: lower large intestine; Int: Intestine; ULI: upper large intestine; UB Wall: Urinary Bladder Wall.

^a Tissue weighting factors according to international commission on radiological protection, ICRP 103 (2007).

Vol:13, No:11, 2019

IV. CONCLUSION

In this study, ⁶⁸Ga-EDTMP was prepared successfully with radiochemical purity of higher than 99%. After injection of final radiolabeled complex into the Wild-type rats, considerable uptake was observed in the bone. Organs with the highest absorbed dose were bone surface and bone marrow (0.112 and 0.053 mSv/MBq, respectively), while, the other organs would not receive significant absorbed dose. Generally, the estimated absorbed dose values are much lower in comparison to the similar radiolabeled complexes.

REFERENCES

- M. G. Agarwal and P. Nayak, "Management of skeletal metastases: An orthopaedic surgeon's guide" Indian J Orthop, vol. 49, pp. 83-100, 2015.
- [2] https://radiopaedia.org/articles/skeletal-metastasis-1. Accessed on: 19/09/2017
- [3] D. W. Kufe, R. E. Pollock, R. R. Weichselbaum, R. C. Bast, T. S. Gansler, J. F. Holland, et al. Holland-Frei Cancer Medicine. 6th ed. Hamilton (ON): BC Decker, 2003.
- [4] H. Yousefnia, S. Zolghadri, H. R. Sadeghi, M. Naderi, A. R. Jalilian and S. Shanesazzadeh, "Preparation and biological assessment of ¹⁷⁷Lu-BPAMD as a high potential agent for bone pain palliation therapy: comparison with ¹⁷⁷Lu-EDTMP" J. Radioanl Nucl Chem, vol. 307, pp. 1243-1251, 2016.
- [5] Lipton, "Pathophysiology of Bone Metastases: How This Knowledge May Lead to Therapeutic Intervention" J Support Oncol, vol. 2, pp. 205-220, 2004.
- [6] H. Yousefnia, S. Zolghadri and A. R. Jalilian, "Preparation and biodistribution assessm ent of 1111n-BPAMD as a novel agent for bone SPECT imagin" J Radiochim Acta, vol. 103, pp. 653-661, 2015.103(9); p. 653-661Radiochimica Acta; ISSN 0033-8230; CODEN RAACAP; v. 103(9); p. 653-661Radiochimica Acta; ISSN 0033-8230; CODEN RAACAP; v. 103(9); p. 653-661Radiochimica Acta; ISSN 0033-8230; CODEN RAACAP; v. 103(9); p. 653-661 Radiochimica Acta; ISSN 0033-8230; CODEN RAACAP; v. 103(9); p. 653-661 Radiochimica Acta; ISSN 0033-8230; CODEN RAACAP; v. 103(9); p. 653-661.
- [7] S. Nilegaonkar, S.Sonar, A. Ranade, and M. Khadilkar, "TC^{99m} MDP bone scan in evaluation of painful scoliosis" Indian J Nucl Med, vol. 25, pp. 67–69, 2010.
- [8] D. Cheng, Y. Wang, X. Liu, P. H.Pretorius, M. Liang, M. Rusckowski, and D. J. Hnatowich, "A comparison of ¹⁸F PET and ^{99m}Tc SPECT imaging in phantoms and in tumored mice" Bioconjug Chem, vol. 21, pp. 1565–1570, 2010.
- [9] B. Koolen, E. Vegt, E. J. Rutgers, W. V. Vogel, M. P. Stokkel, C. A. Hoefnagel, A. Fioole-Bruining, M. J. Vrancken Peeters and R. A. Valdés Olmos, "FDG-avid sclerotic bone metastases in breast cancer patients: a PET/CT case series" Ann Nucl Med, vol. 26, pp. 86-91, 2012.
- [10] T. Uematsu, S. Yuen, S. Yukisawa, T. Aramaki, N. Morimoto, M. Endo, H. Furukawa, Y. Uchida and J. Watanabe, "Comparison of FDG PET and SPECT for detection of bone metastases in breast cancer" AJR Am J Roentgenol, vol. 184, pp1266-1273, 2005.M. Costelloe, H.H. Chuang and J. E. Madewell, "FDG PET for the detection of bone metastases: sensivity, specificity and comparison with other imaging modalities: PET Clin, vol. 5, pp. 281-295, 2010.
- [12] Colleen M. Costelloe Search for articles by this author Affiliations Division of Diagnostic Imaging, Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA Correspondence Search for articles by this author Affiliations Division of Diagnostic Imaging, Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
- [13] Shetty, Y. S. Lee, and J. M. Jeong, "⁶⁸Ga-Labeled Radiopharmaceuticals for Positron Emission Tomography" Nucl Med Mol Imaging, vol.44, pp. 233–240, 2010.
- [14] R. C. Walker, G. T. Smith, E. Liu, B. Moore, J. Clanton and M. Stabin, "Measured Human Dosimetry of ⁶⁸Ga-DOTATATE" J Nucl Med, vol. 54, pp. 855–860, 2013.
- [15] I. Velikyan, "Prospective of ⁶⁸Ga-Radiopharmaceutical Development" Theranostics, vol. 4, pp. 47-80, 2014.

- [16] B. Ramaswamy and C. L. shapiro, "Bisphosphonates in the Prevention and Treatment of Bone Metastases" Available at: http://www.cancernetwork.com/bone-metastases/bisphosphonatesprevention-and-treatment-bone-metastases. Accesses on: 01/09/2003
- [17] Holen and R. E. Coleman, "Bisphosphonates as treatment of bone metastases" Curr Pharm Des, vol. 16, pp. 1262-1271, 2010.
- [18] N. Pfannkuchen, M. Meckel, R. Bergmann, M. Bachmann, C. Bal, M. Sathekge, W. Mohnike, R. P. Baum and F. Rösch, "Novel Radiolabeled Bisphosphonates for PET Diagnosis and Endoradiotherapy of Bone Metastases" Pharmaceuticals, vol. 10, 2017.
- [19] M. Fellner, R. P. Baum, V. Kubícek, P. Hermann, I. Lukes, V. Prasad and F. Rösch, "PET/CT imaging of osteoblastic bone metastases with (68)Ga-bisphosphonates: first human study" Eur J Nucl Med Mol Imaging, vol. 37, pp. 834, 2010.
- [20] Rabie, R. Enayati, H. Yousefnia, A. R, Jalilian, M. Shamsaei, S. Zolghadri, A. Bahrami-samani and M. Hosntalab, "Preparation, quality control and biodistribution assessment of ¹⁵³Sm-BPAMD as a novel agent for bone pain palliation therapy"Ann Nucl Med, vol. 29, pp. 870-876, 2015.
- [21] H. Iagaru, E. Mittra, P. M. Colletti and H. Jadvar, "Bone-Targeted Imaging and Radionuclide Therapy in Prostate Cancer" J Nucl Med, vol. 57, pp. 19-24, 2016.
- [22] Mirzaei , A. R. Jalilian, A. Badbarin, M. Mazidi, F. Mirshojaei, P. Geramifar and D. Beiki, "Optimized production and quality control of (68)Ga-EDTMP for small clinical trials" Ann Nucl Med, vol. 29, pp. 506-511, 2015.
- [23] Sparks RB, Aydogan B. Comparison of the effectiveness of some common animal data scaling techniques in estimating human radiation dose. Sixth International Radiopharmaceutical Dosimetry Symposium, Oak Ridge, TN: Oak Ridge Associated Universities; pp. 705–716, 1996.
- [24] M. G. Stabin and J. A. Siegel. "Physical Models and Dose Factors for Use in Internal Dose Assessment" Health Phys, vol. 85, pp. 294-310, 2003.